CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO
DEA Targets Synthetic Drug Manufacturers Nationwide
On May 7, 2014, the Drug Enforcement Administration (DEA) announced the culmination of their nationwide crackdown on the synthetic drug industry. This joint effort between the DEA, Customs and Border Protection (CBP), Federal Bureau of Investigation (FBI), the Internal Revenue Service (IRS), and local agencies is called Project Synergy Phase II and was carried out in more than 29 states (DEA News: Huge Synthetic Drug Takedown).
 
Law enforcement officials across the US arrested more than 150 individuals and seized hundreds of thousands of ready-to-sell synthetic drugs, kilograms worth of precursor chemicals, and $20 million in cash and assets. “Many who manufacture, distribute and sell these dangerous synthetic drugs found out first hand today that DEA will target, find, and prosecute those who have committed these crimes,” commented DEA Administrator Michele M. Leonhart.
 
Designer synthetic drugs that mimic marijuana, cocaine, LSD and amphetamines, have become increasingly popular with drug users because of their wide availability on the internet and at head shops. These drugs are often more potent and dangerous than the compounds they mimic and in the past couple of years, have accounted for more emergency room visits.
 
Cerilliant offers certified Snap-N-Spike® solutions for a variety of synthetic drugs, their metabolites, and internal standards, from synthetic cannabinoids, synthetic cathinones, first and second generation 2C phenethylamines, and benzyl and phenyl piperazines to designer benzodiazepines, opioids, amphetamines, and hallucinogens. These drugs of abuse reference standards are suitable for use in numerous GC/MS or LC/MS testing applications from urine drug monitoring and forensic testing to clinical toxicology analysis.
 
Cerilliant’s synthetic drug reference standards are manufactured and certified to the highest industry standards including ISO Guide 34, ISO/IEC 17025, and ISO 13485. Since the majority of synthetic drugs are classified as controlled substances, Cerilliant supplies most of these reference standards as DEA-exempt solutions for added convenience. Click on the links below to view Cerilliant Certified Spiking Solutions® of designer synthetic drugs:
 


Return to Article List


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn